Lisa A. Jackson, MD, MPH
“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”
Lisa A. Jackson, MD, MPH
Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine
Biography
Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Research interests and experience
Vaccines & Infectious Diseases
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Recent publications
Jackson LA, Coler RN, Deye GA, Carter D, Gray SA, Pecor T, Davis J, Larsen SE, Posavad CM, Cox C, Watanabe A, Lundeen JS, Gill R, Kalyanasundaram A, Siddiqui AA Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine 2025 Nov 24;10(1):247. doi: 10.1038/s41541-025-01261-3. Epub 2025-11-24. PubMed
Fitz-Patrick D, McVinnie DS, Jackson LA, Crowther G, Geevarughese A, Cannon KD, Garcia LM, Pineiro Puebla Y, Yi Z, Cunliffe L, Maniar A, Zareba AM, Ianos CA, Gomme E, Koury K, Suphaphiphat Allen P, Anderson AS, Gurtman A, Lindert K, Pfizer C4781004 Trial Investigators Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine 2025 Nov 20;393(20):2001-2011. doi: 10.1056/NEJMoa2416779. PubMed
Donahue JG, Cocoros NM, Kieke BA, Hanson KE, Weintraub ES, Yih WK, Scotty E, McClure DL, Fireman B, Boyce TG, Maro JC, Bartlett J, Glanz JM, Haapala JL, Horberg M, Hurley L, Irving SA, Jackson LA, Kim S, Klein NP, McNeil MM, Myers TR, Qian L, Smith N, Sundaram ME, Tartof S, Wang L, Xu S, Belongia EA Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink 2025 Nov 20;67:127873 doi:10.1016/j.vaccine.2025.127873. doi: 10.1016/j.vaccine.2025.127873. Epub 2025-10-24. PubMed
Atmar RL, Lyke KE, Posavad CM, Deming ME, Brady RC, Dobrzynski D, Edupuganti S, Mulligan MJ, Rupp RE, Rostad CA, Jackson LA, Martin JM, Shriver MC, Rajakumar K, Coler RN, El Sahly HM, Kottkamp AC, Branche AR, Frenck RW, Johnston C, Babu TM, Bäcker M, Archer JI, Crandon S, Nakamura A, Nayak SU, Szydlo D, Dominguez Islas CP, Brown ER, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Beigel JH, Pasetti M, Roberts PC Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine 2025 Oct 15;232(4):971-981 doi:10.1093/infdis/jiaf176. doi: 10.1093/infdis/jiaf176. Epub 2025-04-29. PubMed
Dobrzynski DM, Graciaa DS, Babu TM, Coler RN, Paulsen GC, Hoft DF, Frey SE, Edwards KM, Jackson LA, Chen WH From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units 2025 Oct 10;81(Supplement_2):S125-S136. doi: 10.1093/cid/ciaf379. PubMed
Irving SA, Groom HC, Belongia EA, Crane B, Daley MF, Jackson LA, Kenigsberg TA, Kuckler L, Tseng HF, Williams JTB, Zerbo O, Naleway AL Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons 2025 Oct 3;64:127667 doi:10.1016/j.vaccine.2025.127667. doi: 10.1016/j.vaccine.2025.127667. Epub 2025-09-04. PubMed
Diemert DJ, Graciaa DS, Zhang B, Rouphael NG, Branche AR, Martin TCS, Jackson LA, Presti RM, Kamidani S, Mahgoub SM, Babu TM, Magaret CA, Simon V, van Bakel H, Roberts PC, Beigel JH, Gilbert PB, Follmann D Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial 2025 Oct 3;64:127718 doi:10.1016/j.vaccine.2025.127718. doi: 10.1016/j.vaccine.2025.127718. Epub 2025-09-09. PubMed
Jatt LP, Gillespie KM, Van P, Hoffman SL, Jackson LA, Murphy SC, Heath JR, Kublin JG Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection 2025 Aug 14 doi: 10.1093/infdis/jiaf435. Epub 2025-08-14. PubMed
Duffy J, Yih WK, Walton K, DeSilva MB, Glanz JM, Hambidge SJ, Jackson LA, Klein NP, Lewin BJ, Naleway AL, Sundaram ME, Maro JC, Weintraub E JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States 2025 Aug;53(4):1321-1328. doi: 10.1007/s15010-024-02428-1. Epub 2024-11-20. PubMed
Kifle DW, Kalyanasundaram A, Molehin AJ, Balkhi MY, Arya A, Zhang W, Ahmad G, Torben W, Carey D, Papin JF, Jackson LA, Gray SA, Carter D, Siddiqui AA Potential biomarker and composite efficacy readout for human clinical trials of schistosomiasis vaccine in Africa 2025 Jul 2;15(1):23251. doi: 10.1038/s41598-025-05730-6. Epub 2025-07-02. PubMed
News
Vaccine program recruiting volunteers in Seattle area
KPWHRI’s vaccine registry was the first to enroll participants in a clinical trial of a COVID-19 vaccine.
News
Clinical trial will evaluate mpox vaccine for adolescents
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
Research
New study confirms safety of shingles vaccine
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Research
‘Fighting back’ against COVID-19: Remembering a historic trial
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.